Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Diseases of the Thyroid

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 20 articles: HTML format

Single Articles

September 2023
1. DUKE ES, Bradford D, Marcovitz M, Amatya AK, et al
   FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors.
   Clin Cancer Res. 2023;29:3573-3578.
   PubMed     Abstract available
   
   
   August 2023
2. CHI Y, Zheng X, Zhang Y, Shi F, et al
   Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase â…¡ Trial.
   Clin Cancer Res. 2023 Aug 18:CCR-22-3406. doi: 10.1158/1078-0432.CCR-22-3406.
   PubMed     Abstract available
   
   
   June 2023
3. HU H, Ng TSC, Kang M, Scott E, et al
   Thyroid cancers exhibit oncogene-enhanced macropinocytosis that is restrained by IGF1R and promotes albumin-drug-conjugate response.
   Clin Cancer Res. 2023 Jun 8:CCR-22-2976. doi: 10.1158/1078-0432.CCR-22-2976.
   PubMed     Abstract available
   
   
   
4. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
   Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
   Clin Cancer Res. 2023 Jun 1:OF1-OF8. doi: 10.1158/1078-0432.CCR-23-0278.
   PubMed     Abstract available
   
   
   May 2023
5. BIKAS A, Ahmadi S, Pappa T, Marqusee E, et al
   Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes.
   Clin Cancer Res. 2023 May 16:CCR-23-0278. doi: 10.1158/1078-0432.CCR-23-0278.
   PubMed     Abstract available
   
   
   
6. LIN Y, Qin S, Yang H, Shi F, et al
   Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer.
   Clin Cancer Res. 2023 May 15:CCR-22-3613. doi: 10.1158/1078-0432.CCR-22-3613.
   PubMed     Abstract available
   
   
   April 2023
7. LEBOULLEUX S, Do Cao C, Zerdoud S, Attard M, et al
   A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E Mutated Differentiated thyroid Cancer.
   Clin Cancer Res. 2023 Apr 19:CCR-23-0046. doi: 10.1158/1078-0432.CCR-23-0046.
   PubMed     Abstract available
   
   
   February 2023
8. BOUCAI L, Saqcena M, Kuo F, Grewal RK, et al
   Genomic and transcriptomic characteristics of metastatic thyroid cancers with exceptional responses to radioactive iodine therapy.
   Clin Cancer Res. 2023 Feb 13:CCR-22-2882. doi: 10.1158/1078-0432.CCR-22-2882.
   PubMed     Abstract available
   
   
   October 2022
9. CABANILLAS ME, Busaidy NL, Sherman SI
   Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.
   Clin Cancer Res. 2022;28:4164-4166.
   PubMed     Abstract available
   
   
   June 2022
10. DUKE ES, Barone AK, Chatterjee S, Mishra-Kalyani PS, et al
    FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer.
    Clin Cancer Res. 2022 Jun 9. pii: 704846. doi: 10.1158/1078-0432.CCR-22-0873.
    PubMed     Abstract available
    
    
    May 2022
11. WEBER M, Kersting D, Riemann B, Brandenburg T, et al
    Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancer With MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study.
    Clin Cancer Res. 2022 May 20. pii: 699089. doi: 10.1158/1078-0432.CCR-22-0437.
    PubMed     Abstract available
    
    
    July 2021
12. ZHENG X, Xu Z, Ji Q, Ge M, et al
    A randomized, phase 3 study of lenvatinib in Chinese patients with radioiodine-refractory differentiated thyroid cancer.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0761.
    PubMed     Abstract available
    
    
    
13. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available
    
    
    June 2021
14. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available
    
    
    May 2021
15. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available
    
    
    April 2021
16. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available
    
    
    December 2020
17. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available
    
    
    November 2020
18. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available
    
    
    October 2020
19. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available
    
    
    April 2020
20. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: